Fundraising FoxPerridon Ventures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
NewLimitnewlimit.com𝕏May 2025
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Founder)inBlake Byers(Founder)inJacob Kimmel(Founder)inMichael Polansky(Executive Officer)
BoardZavain Dar(Director)in
Co-investorsS32Valor Equity Partners8VCAbstract Venturesage1Beyond Capital+15 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.